Merck Hit With Antitrust Class Action Over Vaccine Data

Law360, New York (June 25, 2012, 5:05 PM EDT) -- Merck and Co. Inc. was hit with a putative antitrust class action in Pennsylvania federal court Friday by an Alabama medical provider alleging the pharmaceutical company lied about the efficacy rate of its mumps inoculation in an effort to keep competitors from bringing their own versions of the vaccine to market.

Chatom Primary Care PC accuses Merck of concealing test results and falsifying studies to artificially maintain the vaccine’s claimed 95 percent efficacy rate and intimidate rivals from producing their own version. Since 1967, Merck has...
To view the full article, register now.